ConductScience.org, home

Paper28940010

Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.

Horváth B and 8 others. Naunyn Schmiedebergs Arch Pharmacol, 2017. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes. Papers, record 28940010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28940010

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.
PubMed
Journal
Naunyn Schmiedebergs Arch Pharmacol
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
1.4
iCite
Revised in PubMed
2018-11-13
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Horváth BBalázs
2Szentandrássy NNorbert
3Veress RRoland
4Almássy JJános
5Magyar JJános
6Bányász TTamás
7Tóth AAttila
8Papp ZZoltán
9Nánási PPPéter P

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Myocytes, CardiacMajor topic
UreaMajor topic
Action Potentials
Animals
Calcium Signaling
Cell Size
Diastole
Dogs
Female
Heart Ventricles
Male
Myocardial Contraction
Myosins
Systole

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
K115397National Research Development and Innovation OfficePubMed
K109736National Research Development and Innovation OfficePubMed
K101196National Research Development and Innovation OfficePubMed
GINOP-2.3.2.-15-2016-00040European Union and European Regional Development FundPubMed

Source PubMed

Download CSV of grants

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123250339Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells.Naunyn Schmiedebergs Arch Pharmacol2013https://conductscience.org/library/papers/23250339PubMed
226709596Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects.Int J Clin Pharmacol Ther2016https://conductscience.org/library/papers/26709596PubMed
327012405Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.J Am Coll Cardiol2016https://conductscience.org/library/papers/27012405PubMed
421856480Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.Lancet2011https://conductscience.org/library/papers/21856480PubMed
526140433The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat.Br J Pharmacol2015https://conductscience.org/library/papers/26140433PubMed
6253442019-Anthracene carboxylic acid is more suitable than DIDS for characterization of calcium-activated chloride current during canine ventricular action potential.Naunyn Schmiedebergs Arch Pharmacol2015https://conductscience.org/library/papers/25344201PubMed
721187335Mouse intact cardiac myocyte mechanics: cross-bridge and titin-based stress in unactivated cells.J Gen Physiol2011https://conductscience.org/library/papers/21187335PubMed
827779469Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes.J Physiol Pharmacol2016https://conductscience.org/library/papers/27779469PubMed
920498236Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.Circ Heart Fail2010https://conductscience.org/library/papers/20498236PubMed
1021856481The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.Lancet2011https://conductscience.org/library/papers/21856481PubMed
1127914656Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.Lancet2016https://conductscience.org/library/papers/27914656PubMed
1215338108Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.Naunyn Schmiedebergs Arch Pharmacol2004https://conductscience.org/library/papers/15338108PubMed
138766913Action potential duration and force-frequency relationship in isolated rabbit, guinea pig and rat cardiac muscle.J Comp Physiol B1996https://conductscience.org/library/papers/8766913PubMed
1426065842Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.J Cardiovasc Pharmacol2015https://conductscience.org/library/papers/26065842PubMed
1515721865Apico-basal inhomogeneity in distribution of ion channels in canine and human ventricular myocardium.Cardiovasc Res2005https://conductscience.org/library/papers/15721865PubMed
1615952036Asymmetrical distribution of ion channels in canine and human left-ventricular wall: epicardium versus midmyocardium.Pflugers Arch2005https://conductscience.org/library/papers/15952036PubMed
1724566722Asynchronous activation of calcium and potassium currents by isoproterenol in canine ventricular myocytes.Naunyn Schmiedebergs Arch Pharmacol2014https://conductscience.org/library/papers/24566722PubMed
1828082673Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle.J Biol Chem2017https://conductscience.org/library/papers/28082673PubMed
1920668839Effects of ropinirole on action potential characteristics and the underlying ion currents in canine ventricular myocytes.Naunyn Schmiedebergs Arch Pharmacol2010https://conductscience.org/library/papers/20668839PubMed
2025716967Changes in intracellular calcium concentration influence beat-to-beat variability of action potential duration in canine ventricular myocytes.J Physiol Pharmacol2015https://conductscience.org/library/papers/25716967PubMed

See all 29 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
40911791Danicamtiv increases cardiac mechanical efficiency.J Physiol2025https://conductscience.org/library/papers/40911791PubMed
40831223Insights from electromechanical simulations to assess omecamtiv mecarbil efficacy in heart failure.J Physiol2026https://conductscience.org/library/papers/40831223PubMed
40531056Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil's in vivo cardiac effects.J Gen Physiol2025https://conductscience.org/library/papers/40531056PubMed
38566963Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future.Front Cardiovasc Med2024https://conductscience.org/library/papers/38566963PubMed
37239022Characterization of Stimulatory Action on Voltage-Gated Na+ Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator.Biomedicines2023https://conductscience.org/library/papers/37239022PubMed
36986459Drug Candidate BGP-15 Prevents Isoproterenol-Induced Arrhythmias and Alters Heart Rate Variability (HRV) in Telemetry-Implanted Rats.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/36986459PubMed
36722665Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca2+ levels.ESC Heart Fail2023https://conductscience.org/library/papers/36722665PubMed
36613900The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications.Int J Mol Sci2022https://conductscience.org/library/papers/36613900PubMed
36498977Antiarrhythmic and Inotropic Effects of Selective Na+/Ca2+ Exchanger Inhibition: What Can We Learn from the Pharmacological Studies?Int J Mol Sci2022https://conductscience.org/library/papers/36498977PubMed
35784869Effects of Sarcolemmal Background Ca2+ Entry and Sarcoplasmic Ca2+ Leak Currents on Electrophysiology and Ca2+ Transients in Human Ventricular Cardiomyocytes: A Computational Comparison.Front Physiol2022https://conductscience.org/library/papers/35784869PubMed
35229734Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure.J Clin Invest2022https://conductscience.org/library/papers/35229734PubMed
34832924Late Na+ Current Is [Ca2+]i-Dependent in Canine Ventricular Myocytes.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/34832924PubMed
34716531Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action.J Pharmacokinet Pharmacodyn2022https://conductscience.org/library/papers/34716531PubMed
34404848The development of L-type Ca2+ current mediated alternans does not depend on the restitution slope in canine ventricular myocardium.Sci Rep2021https://conductscience.org/library/papers/34404848PubMed
33929079Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.Pharmacol Res Perspect2021https://conductscience.org/library/papers/33929079PubMed
33844095Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.Basic Res Cardiol2021https://conductscience.org/library/papers/33844095PubMed
32969560Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.Pharmacol Res Perspect2020https://conductscience.org/library/papers/32969560PubMed
31999537The Control of Diastolic Calcium in the Heart: Basic Mechanisms and Functional Implications.Circ Res2020https://conductscience.org/library/papers/31999537PubMed
31956082Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency.Stem Cell Reports2020https://conductscience.org/library/papers/31956082PubMed
31541103Simultaneous measurement of excitation-contraction coupling parameters identifies mechanisms underlying contractile responses of hiPSC-derived cardiomyocytes.Nat Commun2019https://conductscience.org/library/papers/31541103PubMed

See all 25 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MYH1479784PubTator's text mininghttps://conductscience.org/library/genes/79784

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28940010

GET https://conductscience.org/api/papers/v1/28940010/references?page=2